Mallolas J, Gatell J M, Gómez-Sirvent J L, Buira E, Zamora L, Alecrim-Andrade J, Adán A, Morales M, Miró J M, Lonća M, Guelar A, Soriano E
Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona.
Enferm Infecc Microbiol Clin. 1997 Feb;15(2):61-4.
An approach of daily or 5 days per week treatment as maintenance therapy is mandatory among HIV patients with CMV retinitis. We evaluate the efficacy and tolerance of thrice weekly maintenance therapy for CMV retinitis in AIDS patients.
Sixty nine consecutive patients with CMV disease were eligible for a prospective open clinical trial. Thirty three completed the induction treatment of CMV retinitis, agreed on maintenance thrice weekly and were included. Twenty nine received Ganciclovir (10 mg/kg/day) and 4 foscarnet (100 mg/kg/day) thrice weekly.
The mean age was 34 years. Twenty nine of the 33 (87%) were males and 13 (39%) drug addicts. Mean CD4+ lymphocyte count at inclusion was 44 cells per relapsed and 22 (66%) died. The median time to relapse, survival free of CMV retinitis and the median survival was 18, 14 and 34 weeks respectively.
Since the outcome of our patients with thrice weekly maintenance therapy was similar to historical controls our study at least provides the rational for this hypothesis to be tested in a future randomised trial.
对于患有巨细胞病毒性视网膜炎的艾滋病患者，采用每日或每周5天治疗作为维持疗法是必要的。我们评估了艾滋病患者每周三次维持疗法治疗巨细胞病毒性视网膜炎的疗效和耐受性。
69例连续的巨细胞病毒疾病患者符合一项前瞻性开放临床试验的条件。33例完成了巨细胞病毒性视网膜炎的诱导治疗，同意每周三次维持治疗并被纳入研究。29例接受更昔洛韦（10mg/kg/天），4例接受膦甲酸钠（100mg/kg/天），均为每周三次。
平均年龄为34岁。33例中有29例（87%）为男性，13例（39%）为吸毒者。纳入时的平均CD4+淋巴细胞计数为每微升44个细胞。复发时平均CD4+淋巴细胞计数为每微升22个细胞，22例（66%）死亡。复发的中位时间、无巨细胞病毒性视网膜炎生存时间和中位生存时间分别为18周、14周和34周。
由于我们的患者每周三次维持疗法的结果与历史对照相似，我们的研究至少为在未来的随机试验中检验这一假设提供了理论依据。
